We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Drug Products » European Drug Assessment Policy for Biological Medicine - Webinar Recording/ Transcript

Other Options

Audio Recording/Transcript - Dec. 5, 2017

$287.00

Audio Recording/Transcript - Dec. 5, 2017

$258.00

Audio Recording/Transcript - Dec. 5, 2017

$244.00

Audio Recording/Transcript - Dec. 5, 2017

$230.00

Audio Recording/Transcript - Dec. 5, 2017

$215.00

European Drug Assessment Policy for Biological Medicine - Webinar Recording/ Transcript

$287.00
Drug Products

Product Details

European Drug Assessment Policy for Biological Medicine: Do You Know the Latest Developments—and Is Your Focus on CMC?

Biologics and chemical-based medicines are fundamentally different, nowhere so much as under CMC policy changes set forth recently by the EU. But savvy biologics makers are already seeing a double-barreled opportunity in the EU’s action — avoiding costly compliance errors while boosting sales in the bargain.

Keith Chidwick Ph.D. MBA untangles the complexities of the new European Drug Assessment Policy for Biological Medicines ... and points out the profit opportunities implicit in its provisions.

The impact of the new CMC policy is enormous, affecting drug and biologics makers in dozens of drug development and assessment areas. Dr. Chidwick guides you through the fine print, including key issues such as:

  • Eligibility and requirements to enter the centralized procedure
  • Game-changing issues including comparability, the main CMC reason for refusal
  • QbD as applied to biologics (this one could be your strike-it-rich bonanza!)
  • Strategic validation — understanding the big decisions that begin in early product development
  • Best practices for biosimilars in the EU, given that the CHMP (Committee for Medicinal Products for Human Use) is now experienced in biosimilars and certain common themes have been identified
  • And much more!

This new EU policy is a game-changer for drug and biologics makers. You fail to comply at your peril ... but proper compliance and understanding can fatten the bottom line. Who wouldn’t want that?

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing